Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
NCT03675750 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2019-09-19
Summary
The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.
Conditions
Sponsors & Collaborators
-
Shanghai Mental Health Center
lead OTHER
Principal Investigators
-
LiHua Wang · Shanghai Mental Health Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-07-01
- Primary Completion
- 2020-04-30
- Completion
- 2020-10-31
Countries
- China
Study Locations
More Related Trials
-
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
NCT02751307 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
NCT00448630 ·Status: COMPLETED
-
Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
NCT01206153 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic Side-effects for Second-generation Antipsychotics
NCT01280396 ·Status: COMPLETED
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin for Weight Loss in Schizophrenia
NCT01177709 ·Status: TERMINATED ·Phase: NA
-
AP Metabolism Transcriptomics
NCT06814314 ·Status: RECRUITING
-
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142 ·Status: RECRUITING ·Phase: PHASE3
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients
NCT01300637 ·Status: UNKNOWN ·Phase: NA
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
NCT00625170 ·Status: COMPLETED ·Phase: NA
-
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
NCT00528359 ·Status: COMPLETED
-
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCT03271866 ·Status: UNKNOWN ·Phase: NA
-
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234 ·Status: COMPLETED ·Phase: PHASE4
-
PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
NCT05033119 ·Status: COMPLETED
-
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
NCT07045935 ·Status: RECRUITING ·Phase: PHASE4
-
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCT00816907 ·Status: COMPLETED ·Phase: PHASE4
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
NCT00617240 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective, Open-ended, Multi-center Study of Schizophrenia Patients Switching to Zolodine
NCT04975035 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Berberine Treat Metabolic Syndrome in Schizophrenia
NCT03251716 ·Status: COMPLETED ·Phase: NA
-
A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics
NCT00480168 ·Status: COMPLETED